Alpha Cognition (NASDAQ:ACOG) Cut to Sell at Wall Street Zen

Wall Street Zen lowered shares of Alpha Cognition (NASDAQ:ACOG – Free Report) from a hold rating to a sell rating in a report released on Saturday,Wall Street Zen reports.

Several other research firms have also weighed in on ACOG. Raymond James Financial set a $21.00 price target on Alpha Cognition and gave the company an “outperform” rating in a report on Thursday. HC Wainwright lifted their price objective on shares of Alpha Cognition from $18.00 to $20.00 and gave the stock a “buy” rating in a research note on Monday, August 17th. Craig Hallum reiterated a “buy” rating and set a $17.00 price objective on shares of Alpha Cognition in a research report on Friday, August 14th. Finally, B. Riley Financial started coverage on shares of Alpha Cognition in a research note on Thursday, August 20th. They issued a “buy” rating and a $21.00 target price on the stock. Five analysts have rated the stock with a Buy rating. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $18.20.

Read Our Latest Stock Report on Alpha Cognition

Alpha Cognition Stock Performance

Shares of ACOG stock opened at $7.83 on Friday. Alpha Cognition has a 1 year low of $4.50 and a 1 year high of $10.14. The stock’s 50 day simple moving average is $8.70 and its two-hundred day simple moving average is $7.29.

Alpha Cognition (NASDAQ:ACOG – Get Free Report) last announced its earnings results on Wednesday, November 11th. The company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01). The company had revenue of $7.78 million during the quarter, compared to analysts’ expectations of $7.04 million. Alpha Cognition had a negative return on equity of 50.90% and a negative net margin of 147.26%. As a group, sell-side analysts forecast that Alpha Cognition will post -1.27 EPS for the current year.

Insider Transactions at Alpha Cognition

In other Alpha Cognition news, Director Robert Wills bought 10,000 shares of the company’s stock in a transaction on Friday, August 21st. The stock was acquired at an average price of $9.62 per share, for a total transaction of $96,200.00. Following the completion of the transaction, the director directly owned 32,241 shares of the company’s stock, valued at approximately $310,158.42. This represents a 44.96% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 8.60% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Alpha Cognition

Several hedge funds and other institutional investors have recently modified their holdings of ACOG. AWM Investment Company Inc. purchased a new stake in shares of Alpha Cognition during the second quarter valued at $12,073,000. Opaleye Management Inc. grew its holdings in shares of Alpha Cognition by 13.0% in the second quarter. Opaleye Management Inc. now owns 2,895,467 shares of the company’s stock worth $20,905,000 after purchasing an additional 333,517 shares during the last quarter. ACT Capital Partners L.P. bought a new position in shares of Alpha Cognition in the third quarter worth about $464,000. Marshall Wace LLP bought a new position in shares of Alpha Cognition in the third quarter worth about $449,000. Finally, Pekin Hardy Strauss Inc. bought a new position in shares of Alpha Cognition in the third quarter worth about $210,000.

About Alpha Cognition

(Get Free Report)

Alpha Cognition Inc. is a biopharmaceutical company focused on developing treatments for people with neurodegenerative diseases and cognitive disorders. The company is based in Vancouver, British Columbia. Its lead product, ZUNVEYL (benzgalantamine), is an oral medication approved by the U.S. Food and Drug Administration to treat mild to moderate dementia of the Alzheimer’s type. The company developed benzgalantamine as a prodrug of galantamine. Alpha Cognition is also developing ALPHA-1062 for potential use in other cognitive disorders, including cognitive impairment associated with traumatic brain injury.

See Also

Analyst Recommendations for Alpha Cognition (NASDAQ:ACOG)

Receive News & Ratings for Alpha Cognition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Cognition and related companies with MarketBeat.com's FREE daily email newsletter.